• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Immatics N.V. (Amendment)

    2/7/24 5:02:58 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    SC 13G/A 1 d769663dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)* 

     

     

    IMMATICS N.V.

    (Name of Issuer)

    Ordinary Shares, nominal value €1.00 per share

    (Title of Class of Securities)

    N44445109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13G

    CUSIP No. N44445109

     

     1   

     NAME OF REPORTING PERSONS

     

     ATHOS KG

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Germany

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,911,278

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,911,278

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,911,278

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.8%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

    2


    SCHEDULE 13G

    CUSIP No. N44445109

     

     1   

     NAME OF REPORTING PERSONS

     

     AT Impf GmbH

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Germany

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,911,278

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,911,278

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,911,278

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.8%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

    3


    SCHEDULE 13G

    CUSIP No. N44445109

     

     1   

     NAME OF REPORTING PERSONS

     

     Thomas Maier

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Germany

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,911,278

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,911,278

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,911,278

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.8%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     IN

     

    4


    Item 1(a)      Name of Issuer.   
         The name of the issuer is Immatics N.V. (the “Issuer”).
    Item 1(b)      Address of Issuer’s Principal Executive Offices.   
         The Issuer’s principal executive office is located at Paul-Ehrlich-Straße 15, 72076 Tübingen, Germany.
    Item 2(a)      Name of Person Filing.   
        

    This Amendment No. 1 to Schedule 13G is being jointly filed by ATHOS KG, AT Impf GmbH and Thomas Maier, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”. The sole member of AT Impf GmbH is ATHOS KG and, as a result, ATHOS KG is deemed to be the beneficial owner of the securities held by AT Impf GmbH. Thomas Maier is the general partner (komplementär) of ATHOS KG. The limited partners (kommanditisten) of ATHOS KG are members of the families of Thomas and Andreas Strüngmann.

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated August 16, 2023, which was attached as Exhibit 1 to Schedule 13G filed by the Reporting Persons, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

    Item 2(b)      Address of Principal Business Office or, if none, Residence.
        

    The address of the principal business office of each of the Reporting Persons is Bergfeldstraße 9

    83607 Holzkirchen.

    Item 2(c)      Citizenship.   
         ATHOS KG is a German limited partnership (Kommanditgesellschaft); AT Impf GmbH is a German limited liability company (Gesellschaft mit beschränkter Haftung); and Mr. Maier is a citizen of Germany.
    Item 2(d)      Title of Class of Securities.   
         Ordinary Shares, nominal value €1.00 per share
    Item 2(e)      CUSIP No.   
         N44445109
    Item 3      If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:
         Not applicable.   
    Item 4      Ownership.   
         Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a)    Amount beneficially owned:    See the responses to Item 9 on the attached cover pages.
      (b)    Percent of class:    See the responses to Item 11 on the attached cover pages, which were calculated based on 84,656,114 ordinary shares of the Issuer as of September 30, 2023, as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission on November 14, 2023.

     

    5


      (c)    Number of shares as to which such person has:   
        

    (i) Sole power to vote or direct the vote:

       See the responses to Item 5 on the attached cover pages.
        

    (ii)  Shared power to vote or direct the vote:

       See the responses to Item 6 on the attached cover pages.
        

    (iii)  Sole power to dispose or direct the disposition:

       See the responses to Item 7 on the attached cover pages.
        

    (iv) Shared power to dispose or direct the disposition:

       See the responses to Item 8 on the attached cover pages.
    Item 5      Ownership of Five Percent or Less of a Class.
         If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6      Ownership of More Than Five Percent on Behalf of Another Person.
         See responses to Item 2(a) and Item 4.
    Item 7      Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
         See responses to Item 2(a) and Item 4.   
    Item 8      Identification and Classification of Members of the Group.
         Not applicable.   
    Item 9      Notice of Dissolution of Group.   
         Not applicable.   
    Item 10      Certifications.   
         Not applicable.

     

    6


    SIGNATURE

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 7, 2024     ATHOS KG
        By:  

    /s/ Thomas Maier

        Name: Thomas Maier
        Title: Authorized Signatory
        By:  

    /s/ Stephan Sperber

        Name: Stephan Sperber
        Title: Authorized Signatory
    Date: February 7, 2024     AT IMPF GMBH
        By:  

    /s/ Thomas Maier

        Name: Thomas Maier
        Title: Authorized Signatory
        By:  

    /s/ Stephan Sperber

        Name: Stephan Sperber
        Title: Authorized Signatory
    Date: February 7, 2024     THOMAS MAIER
       

    /s/ Thomas Maier

    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Immatics N.V. with a new price target

      Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

      10/7/24 7:57:11 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Immatics N.V.

      Cantor Fitzgerald initiated coverage of Immatics N.V. with a rating of Overweight

      11/2/23 7:08:49 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on Immatics N.V. with a new price target

      Mizuho initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $12.00

      3/31/23 7:22:50 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

      Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois. Updated data from the Phase 1b trial of IMA203 in patients with metastatic melanoma with substantially longer follow-up compared to the last presentation in October 2024, and including data fro

      4/23/25 10:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Announces Full Year 2024 Financial Results and Business Update

      Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6 months mPFS and OS not reached at a mFU time of 8.6 months in advanced melanoma patients; next data update on Phase 1b trial with extended follow-up planned in 2025 Second-generation ACTengine® IMA203CD8 TCR-T (PRAME): Phase 1a data published in November 2024 showed enhanced pharmacology and potency, demonstrating potential to address solid tumor indications with both high- and m

      3/27/25 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Clear Street Launches Healthcare & Biotechnology Equity Research

      Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives

      12/17/24 2:00:00 PM ET
      $CGEM
      $CRGX
      $DCTH
      $ELVN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations

    $IMTX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immatics N.V.

      SCHEDULE 13G/A - Immatics N.V. (0001809196) (Subject)

      5/2/25 5:40:51 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Immatics N.V.

      EFFECT - Immatics N.V. (0001809196) (Filer)

      4/4/25 12:15:25 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form F-3 filed by Immatics N.V.

      F-3 - Immatics N.V. (0001809196) (Filer)

      3/27/25 8:01:41 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 1:28:33 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 6:32:45 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immatics N.V.

      SC 13G/A - Immatics N.V. (0001809196) (Subject)

      11/8/24 10:46:38 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMTX
    Leadership Updates

    Live Leadership Updates

    See more

    $IMTX
    Financials

    Live finance-specific insights

    See more
    • Immatics Appoints Alise Reicin to Board of Directors

      Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics' Board of Directors as the Company

      7/31/24 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

      Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmedIMA203 conti

      10/10/24 6:30:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

      Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and median duration of response not reached at a median follow-up of 14.4 monthsTargeted to enter registration-enabling Phase 2 trial in melanoma in 2024; discussions with FDA ongoing based on recently ob

      11/8/23 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

      Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME Objective response rate (ORR): 64% (7/11) initial ORR at week 6 and 67% (6/9) confirmed ORR at month 3Median duration of response not reached at median follow-up time of 8.5 months at data cut-offObjective responses independent of solid tumor type at low, medium and high PRAME expression levels in checkpoint-refractory cutaneous melanoma, platinum-resistant ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcomaCohort A IMA203 monotherapy TCR-T t

      5/2/23 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care